DGAP-News

Epigenomics AG: Journal of 'Cancer Treatment and Research Communications' Publishes Results of Study with Blood Test Epi proColon(R)

DGAP-News: Epigenomics AG / Key word(s): Scientific publication
Epigenomics AG: Journal of 'Cancer Treatment and Research Communications'
Publishes Results of Study with Blood Test Epi proColon(R)

11.01.2017 / 08:33
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press release

Journal of "Cancer Treatment and Research Communications" Publishes Results
of Study with Blood Test Epi proColon(R)

ADMIT Study Results Demonstrate Higher Uptake of a Colorectal Cancer
Screening Blood Test Compared to a Fecal Test

Berlin (Germany) and Germantown, MD (U.S.A.), January 11, 2017 -
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced
that the results of the ADMIT study have been published in the peer-
reviewed journal Cancer Treatment and Research Communications. Study
results confirm that a blood-based colorectal cancer screening test has the
potential to increase the participation in colorectal cancer screening
compared to a fecal test.

The study demonstrated a 99.5% rate of adherence to CRC screening using Epi
proColon, while the fecal immunochemical test (FIT) showed an adherence
rate of 88.1%. These numbers contrast to a baseline adherence to standard
of care CRC screening of about 20%, as measured in a passive control arm in
which previously non-compliant patients were offered CRC screening tests
(FIT or colonoscopy) as part of their standard of care.

Nicholas Potter, PhD., Executive Vice-President of Clinical Affairs,
Molecular Pathology Laboratory Network and co-author of the ADMIT study,
commented: "Colorectal cancer is one of the most preventable forms of
cancer, but still 1 in 3 or almost 23 million Americans are not up-to-date
with their screenings. The ADMIT study demonstrated that in this
underscreened population, a blood test could become the new "conversation
starter" between patient and practitioner for achieving the desired outcome
of getting more people screened."

Raymond Nungesser, M.D., Family Medicine Practitioner, Geisinger Health
System and co-author of the study, added: "Colorectal cancer screening
rates have been stagnant over the last decade due to the preparation and
sampling barriers. A blood test for colorectal cancer screening mitigates
these barriers and provides healthcare professionals with a new tool to not
only significantly increase the number of individuals screened but that
will also save lives."

Greg Hamilton, Chief Executive Officer of Epigenomics AG, said: "Higher
participation in screening is essential in the fight against colorectal
cancer, which is the second leading cause of cancer death in the United